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• Zoledronic acid acting on both
osteoclast and osteoblast
compartments is a multimodal
therapy to prevent SBD.
Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder, character-
izedbysevereorgancomplication.Sicklebonedisease (SBD)affectsa largepart of theSCD
patient population, and its pathogenesis has been only partially investigated. Here, we
studied bone homeostasis in a humanized mouse model for SCD. Under normoxia, SCD
mice display bone loss and bone impairment, with increased osteoclast and reduced
osteoblast activity. Hypoxia/reperfusion (H/R) stress, mimicking acute vaso-occlusive
crises (VOCs), increasedbone turnover, osteoclast activity (RankL), andosteoclast recruit-
ment (Rank) with upregulation of IL-6 as proresorptive cytokine. This was associated
with further suppression of osteogenic lineage (Runx2, Sparc). To interfere with the
development of SBD, zoledronic acid (Zol), a potent inhibitor of osteoclast activity/
osteoclastogenesis and promoter of osteogenic lineage, was used in H/R-exposedmice.
Zolmarkedly inhibitedosteoclast activityand recruitment, promotingosteogenic lineage.
The recurrent H/R stress further worsened bone structure, increased bone turnover, depressed osteoblastogenesis (Runx2, Sparc),
and increased both osteoclast activity (RankL, Cathepsin k) and osteoclast recruitment (Rank) in SCD mice compared with either
normoxic or single-H/R-episode SCD mice. Zol used before recurrent VOCs prevented bone impairment and promoted osteogenic
lineage. Our findings support the view that SBD is related to osteoblast impairment, and increased osteoclast activity resulted from
local hypoxia, oxidative stress, and the release of proresorptive cytokine such as IL-6. Zol might act on both the osteoclast and
osteoblast compartments as multimodal therapy to prevent SBD. (Blood. 2015;126(20):2320-2328)
Introduction
Sickle cell disease (SCD) is a worldwide distributed hereditary red
cell disorder, which affects approximately 75 000 individuals in the
United States and almost 20 000 to 25 000 individuals in Europe, this
latter mainly related to the immigration ﬂuxes from endemic areas
such as Sub-Saharan Africa to European countries.1-3 Studies of the
global burden of disease have pointed out the invalidating impact
of SCD on patient quality of life.2 This requires the development of
new therapeutic options to treat sickle cell–related acute and chronic
complications.
SCD is caused by a point mutation in the b-globin gene resulting
in the synthesis of pathologic hemoglobin S (HbS). HbS displays
peculiar biochemical characteristics, polymerizing when deoxygen-
ated with associated reduction in cell ion and water content (cell
dehydration), increased red cell density, and further accelerationofHbS
polymerization.4-6 Pathophysiologic studies have shown that dense,
dehydrated red cells play a central role in acute and chronic clinical
manifestations of SCD, in which intravascular sickling in capillaries
and small vessels leads to vaso-occlusion and impaired blood ﬂow
with ischemic/reperfusion injury.4,7-9 In microcirculation, vaso-
occlusive events (VOCs) result from a complex and still only partially
known scenario involving the interactions between different cell types,
including dense red cells, reticulocytes, abnormally activated endothe-
lial cells, leukocytes, platelets, and plasma factors.4,9,10
Target organs, such as bone or lung, are involved in both acute
and chronic clinical manifestations of SCD, related to their peculiar
anatomic organization mainly characterized by sluggish circulation
and relative local hypoxia.11 Although progress has beenmade in the
knowledge of sickle cell–related organ damage,much still remains to
be investigated in the pathogenesis of sickle bone disease (SBD).12-14
Bone imaging studies bymagnetic resonance imaging of SCD patients
in the early phase of VOCs have documented the presence of ab-
normal periosteal signal intensity, which then develops in areas of
bone infarctions.12 Thus, VOCs combined with marrow hyperpla-
sia and inﬂammation have been suggested to contribute to the
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development of SBD.12,13 Recently, a possible role of vitamin D
deﬁciency in SBD has been proposed, which appears to be sub-
ordinated to the primary defect in bone homeostasis.12
Studies in other models have shown that bone remodeling is a
complex process, involving osteoblastic and osteoclastic activity and
promoting bone formation/resorption. To this process, the transcription
factor Runx2 plays a pivotal role for osteoblastic differentiation by
activating downstream genes such as Sparc (osteonectin). However,
the osteoclastic differentiation and activation is related to osteoclast
cell–surface receptor, Rank.15,16
Here we demonstrate that SBD results from the combined reduced
osteoblast recruitment and increased osteoclast activity. Recurrent
hypoxia/reoxygenation (H/R) events, mimicking acute VOCs, activate
osteoclastogenesis and bone turnover. In SCD mice, zoledronic acid
(Zol) ameliorates bone impairment by restraining osteoclast activity in
favor of osteoblasts. In amodel of recurrent VOCs, Zol acts on both the
osteoclast and osteoblast compartments as multimodal therapy, pre-
venting bone loss and bone impairment. Our study is the ﬁrst to report
on osteoblasts in SBD and provides the rationale of Zol as therapeutic
intervention to prevent SBD.
Materials and methods
Mouse model and study design
Experimentswereperformedonhealthycontrol (Hbatm1(HBA)TowHbbtm3(HBG1,HBB)Tow
AA) and SCD (Hbatm1(HBA)Tow Hbbtm2(HBG1,HBB*)Tow SS) mice.8,17 The Insti-
tutional Animal Experimental Committee, University of Verona (CIRSAL),
and the Italian Ministry of Health approved the experimental protocols. Sex-
(M:F ratio 1:1) and age- (16-18weeks)matchedmicewere studied.18Whenever
indicated, mice were exposed to hypoxia (8% oxygen for 10 hours) followed
by 3 hours reoxygenation (21% oxygen) (H/R stress) to mimic a single acute
VOC as previously described.17,19,20 For recurrent VOCs, AA and SS mice
were exposed to 3 times VOC (8% oxygen for 10 hours followed by 3 hours
reoxygenation on 21% oxygen) with a 3-week interval between each VOC.
Hematologic parameters, red cell indices, and reticulocyte counts were
determined as previously reported.21,22 Bloodwas collectedwith retro-orbital
venipuncture in anesthetized mice using heparin microcapillary tubes. He-
matologic parameters were evaluated on a Technicon Analyzer ADVIA
(Bayer). Hematocrit and hemoglobin measurements were determined man-
ually. Whenever indicated, Zol was administrated at a dosage of 100 mg/kg
intraperitoneally (IP) based on previous reports.23,24
Flow cytometric analysis of mouse erythroid precursors of
murine bone marrow erythroblasts
Flow cytometric analysis of erythroid precursors from bone marrow and spleen
of mice from the 4 strains was carried out as previously described using the
CD44-TER-119 strategy.25,26
Measurements of bone homeostasis and turnover
For details of bone histomorphometry and bone turnover, see supplemental
Methods, available on the BloodWeb site.27-30 The number of nodes (branch
points) and termini (the end points) in a trabecular network, which was skel-
etonized to facilitate examination of its topologic properties, were analyzed
according to Garrahan et al.31 In a bone section, the ratio of nodes to termini
(Nd/Tm) is an index of spatial connectivity. Thus, higher values correspond to
better connectivity.32 In bone histomorphometry,marrow star volume (MSV)
is deﬁned as the mean volume of all parts of an object that can be seen un-
obscured from a random point within the object.33 Higher values of MSV
correspond to reduced connectivity.33 To evaluate bone resorption, the
number of osteoclast/tissue area (NOc/TA) and erosion surface/bone surface
(ES/BS), corresponding to bone covered by eroded cavities, were measured
according to international guidelines.29
Colony-forming unit–osteoblast assay
A colony-forming unit–osteoblast (CFU-Ob) assay was conducted as previ-
ously reported.34 Brieﬂy, 13 106 bone marrow nucleated cells from AA and
SS mice were seeded in 60-mm culture dishes in osteogenic differentiation
medium (a-minimum essential medium supplemented with 50 mg/mL
L-ascorbic acid and 2.0 mM b-glycerophosphate) and incubated at 37°C
under a humidiﬁed atmosphere of 5% CO2. The medium was changed every
2 days, and after 21 days of culture, CFU-Ob colonies were identiﬁed by
alizarin red staining as previously described.34,35
Bone total RNA extraction and reverse transcription
Total RNAwas extracted from each pellet using the RNeasyminikit (QIAGEN,
Milano Italy) with DNAse I treatment. Tibia bones were harvested frommice
and any attached tissue was removed before RNAlater solution (Thermo
Fisher) was added and stored at 4°C. After 24 hours, the RNAlater was elim-
inated and the samples were stored at 280°C until RNA extraction. Frozen
samples were crushed using a mortar and pestle in liquid nitrogen as pre-
viously described36 and then homogenized in RLT Lysis buffer. Details are
reported in the supplemental Methods. Real-time polymerase chain reaction
was performed as previously described.37 Details are reported in the sup-
plemental Methods.
Serum bone alkaline phosphatase and CTX-I evaluation
Sera were collected and stored at280° until analysis. The amounts of bone
alkaline phosphatase (ALP) and CTX-I were determined using a mouse
bone–speciﬁc alkaline phosphatase (BALP) Elisa Kit (CSB-E11914m;
Cusabio) and the CTX –I ELISA kit (CSB-E12782m; Cusabio), respec-
tively. The assays were performed on 96-well immunoplates, according to
the manufacturer instructions.
Statistical analysis
Statistical analyseswereperformedusingSPSS forWindowsversion21.0 (SPSS
Inc./IBM, Armonk, NY). The 2-way analysis of variance algorithm for repeated
measures was used for data analysis. Differences with P, .05 were considered
signiﬁcant.
Results
Sickle cell mice show bone structure impairment and increases
osteoclast activity
Tostudy thepathogenesisofSBDrelated to thehematologicphenotype,
we studied humanized SS mice fed with a standard diet containing
0.97% calcium, 0.85% phosphorus, 1045 U/kg vitamin D3, 22.5%
protein, 5.5% fat, and 52% carbohydrate to avoid confounding con-
tribution of vitamin D deﬁciency on bone homeostasis. SCD mice
displayed reduced node number and node/termini ratio with increased
MSVcomparedwith controlmice expressingnormal hemoglobin (AA),
suggesting an impairment of bone microarchitecture (Figure 1A). In
SCDmice, we also found erythroid hyperplasia without perturbation of
erythroid maturation proﬁle compared with controls similarly to human
SCD subjects and in agreement with the increasedMSVdocumented in
SCD mice (supplemental Figure 1A).
Bone volume was signiﬁcantly decreased in SCD compared with
healthy mice (Figure 1B). Trabecular width and thickness were de-
creased, whereas the trabecular separation was increased in SCD mice
compared with controls, indicating the presence of bone loss in SCD
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mice (Figure 1B). This ﬁnding is in agreement with a previous prelim-
inary report in the same mouse model.18
Because bone homeostasis is mainly related to the balance between
bone resorption/bone formation, we evaluated osteoblast/osteoclast
function in bothmouse strains. In SCDmice,we found reducednumber
of osteoblasts (OBs/BS, Figure 1C;N.Ob/BS, supplemental Figure 1B)
associated with decreased osteoid surface (Figure 1C), indicating a
lower osteoblast activity in SCD compared with healthy mice. These
ﬁndings were in agreement with the downregulation of molecular
osteogenic markers such as Runx2 and Sparc (osteonectin) in SCD
mice (Figure 1D). However, osteoclastic activity was markedly in-
creased as supported by a higher osteoclast number associated with
increased erosion surface in SCD mice compared with controls
(Figure 1C). RankL, a marker of osteoclast activation, was signif-
icantly upregulated in SCD mice compared with healthy controls
(Figure 1D), although no signiﬁcant changes in the expression of
Rank, a marker of osteoclast recruitment, was observed in SCD
mice (Figure 1D). We also analyzed the expression of IL-6, a pro-
resorptive cytokine that cooperates with RankL on osteoclast acti-
vation.38,39 As shown in Figure 1D, IL-6 expressionwas upregulated
in SCD mice compared with controls. These data indicate increased
osteoclast activity combined with possible perturbation of the
osteoprogenitor compartment in SCD mice. Indeed, we found
a decreased ability of mesenchymal stem cells (MSCs) from SCD
mice to form osteoblast-CFUs compared with healthy controls,
suggesting a defect in MSC recruitment to osteoblasts in SCDmice
(Figure 1E).
Because antioxidant systems, such as peroxiredoxin-2 (Prx2)
or catalase, have been recently reported to negatively regulate
osteoclastogenesis, we analyzed the expression of both antioxidant
systems in bones from both SCD and control mice.40,41 Prx2 gene
expression was markedly upregulated in SCD mice compared with
Figure 1. Sickle cell mice display bone impairment, increased osteoclast activity, and suppression of osteoblastogenesis. Beneficial effects of zoledronic acid
(Zol) on osteoclast activity in sickle cell mice. (A) Quantitative histomorphometry of the distal femur of healthy (AA) and sickle cell (SS) mice. Upper panel:
representative undecalcified section of distal femur stained with trichrome Goldner’s stain. Lower panel: MSV, marrow star volume; NdN/TV, node number/tissue volume;
NdN/Tm, node to termini ratio. Data are shown as mean 6 standard deviation (SD) (n 5 6); *P , .05 compared with healthy mice. (B) Bone volume (BV)/tissue volume
(TV), trabecular thickness, trabecular number, and trabecular separation measured by Bone Explora Nova 3.5 image analyzer. Data are shown as mean 6 SD (n 5 6);
*P , .05 compared with healthy mice. (C) ObS/ BS, osteoblast surface/bone surface; OS/BS, osteoid surface/bone surface; N.Oc/TA, osteoclast number/tissue area;
ES/BS, Erosion surface/bone surface. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with healthy mice. (D) Real-Time PCR analysis of Runx2, Sparc,
RankL, Rank, and Il6. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with healthy mice. (E) To assess the number of osteoprogenitors, bone
marrow–derived cells were cultured in vitro under osteogenic differentiation conditions. The CFU-Ob obtained from the MSCs of AA and SS mice were stained by alizarin
red (upper panel) and quantified (#CFU-Ob/dish) (lower panel); data are shown as mean 6 SD (n 5 3; P , .05 AA vs SS). (F) ES/BS, erosion surface/bone surface;
N.Oc/TA, osteoclast number/tissue area in AA and SS mice with and without Zol treatment (100 mg/kg IP). Data are shown as mean 6 SD (n 5 6); *P , .05 compared
with healthy mice; °P , .05 compared with vehicle-treated mice.
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healthy controls (supplemental Figure 1C), whereas Catalase ex-
pression was similar in both mouse strains (data not shown).
No changes in bone turnover, measured by calcein double-
labeling, were present in SCD mice compared with controls, which
was combined with similar levels of carboxy-terminal collagen cross-
links (CTX-I) in both mouse strains (data not shown).
These data suggest that SBD is sustained by a shift in the
balance between osteoblast/osteoclast activity toward osteoclasts
and the upregulation of Prx2 antioxidant system as a back-up
mechanism to control oxidative stress and limit osteoclast activity
in SCD mice.
Zoledronic acid prevents bone loss and ameliorates osteogenic
differentiation in SCD mice
Until now, Zol is considered the most powerful amino-bisphosphonate
that inhibits osteoclast activity and osteoclastogenesis and promotes
osteogenic differentiation.27,28 We then treated SCD and control mice
with Zol (100 mg/kg IP, single dose)23 to investigate whether it might
effectively counteract bone impairment of SCD mice.
Zol signiﬁcantly reduced osteoclast number and erosion surface
in SCD mice without major changes in healthy mice (Figure 1E).
Thiswas associatedwith upregulation ofRunx2 and Sparc (osteonectin)
and downregulation of Rank genes expression in bothmousemodels
(supplemental Figure 2).Prx2 expressionwasmarkedly decreased in
Zol-treated SCD mice compared with vehicle-treated mice (supple-
mental Figure 2).
Taken together, these data suggest that in SCD mice, Zol de-
creases osteoclastic activity and promotes osteoblastogenesis in
SCD mice.
Hypoxia/reoxygenation stress mimics acute vaso-occlusive
crisis and increases bone turnover in SCD mice
Previous studies have shown that H/R stress mimics acute VOC in
different mouse models for SCD.17,21,22 Thus, we exposed SCD and
Figure 2. Hypoxia/reoxygenation stress (H/R) affects bone homeostasis in sickle cell mice. Zoledronic acid prevents H/R-induced increased turnover and osteoclast
activation. (A) Left panel: representative images of calcein-labeled bone surface. Right panel: bone formation rate (BFR/BS) and activation frequency (AcF) in healthy (AA)
and sickle cell (SS) mice under normoxia and exposed to H/R stress. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with AA; °P , .05 compared with normoxic
mice. (B) N.Oc/TA, osteoclast number/tissue area; ES/BS, erosion surface/bone surface in AA and SS mice under normoxia and exposed to H/R stress. Data are shown as
mean 6 SD (n 5 6); *P , .05 compared with AA; °P , .05 compared with normoxic mice. (C) Serum levels of bone alkaline phosphatase (bALP) and carboxy-terminal
collagen crosslinks (CTX-I) in AA and SS mice under normoxia and exposed to H/R stress. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with AA; °P , .05
compared with normoxic mice. (D) Left panel: representative images of calcein-labeled bone surface. Right panel: BRF/BS and AcF in AA and SS mice exposed to H/R stress
without and with Zol treatment before (pre-Zol) or after (Zol-post) H/R stress. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with healthy mice; °P , .05
compared with vehicle treated mice; ^P , .05 Zol-pre compared with Zol-post. (E) N.Oc/TA and ES/BS in AA and SS mice exposed to H/R stress without and with Zol
treatment before (Zol-pre) or after (Zol-post) H/R stress. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with AA; °P , .05 compared with vehicle-treated mice.
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healthy mice to H/R stress. As previously reported, H/R stress in-
duced increased neutrophil count and decreased hemoglobin levels
(supplemental Table 1).17 Increased bone turnover induced by H/R
stress was present in bothmouse groups andwas higher in SCDmice
compared with controls (Figure 2A and supplemental Table 2). This
was associated with signiﬁcant increases in osteoclast number and
erosion surface in SCD mice only (Figure 2B). bALP increased in
both AA and SS mice exposed to H/R, whereas CTX-I significantly
increased in SCD mice only (Figure 2C).
In both mouse strains, H/R stress induced a downregulation of
Runx2 and Sparc (osteonectin), suggesting reduced osteoblast dif-
ferentiation (Runx2) and activity (Sparc, osteonectin) (supplemental
Figure 3). This was associatedwith upregulation ofRankL andRank,
indicating increased osteoclast activity and recruitment (supple-
mental Figure 3).
Zol, administrated before or after H/R stress, prevented theH/R-
induced increased bone turnover in both mouse strains. It is of
interest to note that in SCD mice, pre-H/R administration of Zol
was more efﬁcient in reducing bone turnover than Zol adminis-
trated after H/R stress (Figure 2D). Zol treatment was also able to
signiﬁcantly reduce osteoclast number and activity in both mouse
strains (Figure 2E).
Because the administration of Zol before H/R event seemed to
be more effective on bone homeostasis than after H/R, we analyzed
molecular markers of osteoblast/osteoclastogenesis in mice without
or with Zol treatment administrated before H/R event. Zol prevented
the H/R-induced downregulation of Runx2 and Sparc and H/R-
induced upregulation of RankL and Rank gene expression in both
mouse strains (Figure 3A).We then analyzed IL-6 gene expression in
mice exposed to H/R stress with and without Zol treatment. As
shown in Figure 3B, Zol prevented the H/R-induced upregulation of
IL-6 in both mouse strains, possibly through the modulation of H/R-
induced increased osteoclast activity as previously reported for other
aminobisphosphonates.42 With reduction in osteoclast activity
and recruitment, we consistently observed a downregulation of
H/R-induced increases in Prx2 expression in both mouse strains
(Figure 3C). No further changes in bone microarchitecture related
to a single H/R event were observed in both healthy and SCD mice
(data not shown).
The present data suggest that each acute VOC promotes oste-
oclast recruitment and activation, increases bone turnover, inhibits
osteogenesis, and promotes bone loss in SCD mice. Zol efﬁciently
prevents H/R-induced bone impairment and may be considered an
interesting new treatment to prevent or limit SBD.
In SCD mice, recurrent H/R events cause severe bone
impairment and bone loss
BecauseSCDpatients experience recurrentVOCs,11weexposedSCD
and healthy mice to recurrent H/R stress (10 hours on 8% oxygen
followed by reoxygenation) once every 3 weeks repeated 3 times
(3 times in 9 weeks). In SCD mice, the recurrent VOCs worsened
Figure 3. Hypoxia/reoxygenation stress (H/R) downregulates osteoblastogenesis, induces osteoclastogenesis, upregulates peroxiredoxin-2, anti-oxidant system.
Zoledronic acid plays a preventing role in H/R-induced molecular bone expression. Runx2, Sparc, RankL, and Rank (A), IL-6 (B), and Prx2 (C) mRNA fold change in healthy
(AA) and sickle cell (SS) mice exposed to H/R stress without and with Zol treatment before (pre-Zol). The fold change for each gene expression was obtained by using 2
different housekeeping genes (Gapdh and b-Actin). Data are shown as mean 6 SD (n 5 6); *P , .05; **P , .005.
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anemia andwere associatedwith amarked increase in neutrophil count
compared with either normoxic SCDmice or healthy mice exposed to
recurrent H/R stress (supplemental Table 3). As shown in Figure 4A-B,
recurrent VOCs severely worsened bone microarchitecture as sup-
ported by increased MSV, reduced node numbers, and node/termini
ratio compared with controls (Figure 4A, right panel, and supple-
mental Figure 4A). SCD mice undergoing recurrent VOCs also
showed reduced trabecular bone volume and number associatedwith
increased trabecular separation compared with normal controls
(Figure 4B). We did not observed major differences in osteoblast
numbers and osteoid surface between the 2mouse strains, suggesting
that recurrent H/R events also affect bone homeostasis in control
mice (data not shown). Osteoclast number and erosion were signiﬁ-
cantly higher in SCD mice compared with controls (Figure 4C).
Interestingly, in healthy and SCD mice exposed to recurrent H/R
events, the osteoclast number and erosion number were signiﬁcantly
higher than those observed under normoxic conditions in bothmouse
strains (P, .05 normoxia vs H/R, Figures 1C and 4C).
In recurrent H/R-exposed mice, calcein double-labeling revealed a
higher bone turnover in SCD compared with healthy mice (Figure 5A,
BFR/BS and AcF). In addition, this was higher in both mouse strains
when comparedwith bone turnover under normoxic conditions (P, .05
normoxia vs H/R, Figures 1C and 5A).
Thesedata indicate that inSCDmice, the recurrentH/Revents result
in bone losswith severe alteration of bone structure and increased bone
turnover. Consistently,Runx2was downregulated, whereasRankL,
Rank, and Cathepsin k were upregulated in SCD mice compared with
healthy mice (Figure 5B). IL-6 and Prx2 expression were again higher
in SCDmice than in controls, supporting the contribution of oxidative
stress in SBD (supplemental Figure 4B).
Zoledronic acid restrains osteoclast activity, ameliorates bone
microarchitecture, and prevents bone loss in SCD mice
exposed to recurrent H/R events
To evaluate the impact of Zol on SBD that resulted from recurrent H/R
events,we treated SCDand controlmicewithZol (100mg/kg IP, single
dose) 1 month before the ﬁrst of the 3 repeated VOC events. As shown
in Figure 4A, Zol signiﬁcantly prevented the H/R-induced micro-
architecture alterations and maintained bone volume and trabecular
thickness, indicating that Zol prevents bone loss and ameliorates bone
microarchitecture in SCD mice (Figure 4A-B). These ﬁndings agreed
Figure 4. Recurrent hypoxia/reoxygenation (H/R) stress mimicking acute vaso-occlusive crisis (VOCs) worsens bone structure in sickle cell mice. (A) Quantitative
histomorphometry of the distal femur of healthy (AA) and sickle cell (SS) mice exposed to recurrent (Rec) acute VOCs without and with Zol treatment. Left panel:
representative undecalcified section of distal femur stained with trichrome Goldner’s stain. Right panel: MSV, marrow star volume; NdN/TV, node number/tissue volume; NdN/
Tm, node to termini ratio. Data are shown as mean 6 SD (n 5 6); P , .05 compared with healthy mice; °P , .05 compared with vehicle-treated mice. (B) Bone volume (BV)/
tissue volume (TV), trabecular thickness, trabecular number, and trabecular separation in healthy (AA) and sickle cell (SS) mice exposed to recurrent (Rec) acute VOCs
without and with Zol treatment. (C) N.Oc/TA, osteoclast tumber/tissue area; ES/BS, erosion surface/bone surface in AA and SS mice exposed to recurrent (Rec) acute VOCs
without and with Zol. Data are shown as mean 6 SD (n 5 6); *P , .05 compared with healthy mice; °P , .05 compared with vehicle-treated mice.
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with the reduction in osteoclast number and erosion surface in Zol-
treated SCDmice comparedwith vehicle-treated mice (Figure 4C). No
major differences were observed in osteoblast number in both Zol- and
vehicle-treated mice (data not shown). The recurrent H/R stress–
induced bone turnover was signiﬁcantly decreased in both Zol-treated
SCD and AA mice compared with vehicle-treated mice (Figure 5A).
In addition, Zol treatment signiﬁcantly increased osteoblastogenesis
(Runx2) and decreased osteoclast activity (RankL, Cathepsin k) and
recruitment (Rank) in both mouse strains exposed to recurrent H/R
stress (Figure 5B). This was associated with downregulation of IL-6
and Prx2 (supplemental Figure 4B) expression in Zol-treated SCD
mice compared with vehicle-treated mice, in agreement with the re-
duction of osteoclast activity.
Our results indicate that Zol prevents the development of SBD in
SCD mice exposed to recurrent VOCs.
Discussion
SBD greatly affects SCD patient quality of life, and its clinical manage-
ment is still unsatisfactory. Limited studies on SBD are available and its
pathogenesis has been only partially investigated.18,43-47
Here we show bone impairment and bone loss in SCD mice under
normoxic conditions. This was associated with downregulation of
osteogenicmarkers (Runx2 andSparc) and increased osteoclast activity
(RankL) without major changes in osteoclastogenesis. Because Runx2
and Sparc explore osteoblast recruitment and differentiation, our
ﬁndings suggest adecreasedMSCcommitment in osteogenic lineage in
SCDmice. Indeed,weobserved a signiﬁcant reduction in thenumber of
CFU-Ob from SCDmice compared with healthy controls (Figure 1E),
supporting the perturbation of osteoprogenitor compartment in favor of
osteoclast activity in SCD mice.
Based on this evidence, we chose Zol as a powerful inhibitor of
osteoclast activity and a promoter of osteogenic differentiation to treat
SBD.27,28 In normoxic SCD mice, Zol reduced osteoclast activity and
improved osteoblastogenesis as supported by the downregulation of
Rank and the upregulation of Runx2 and Sparc, respectively (sup-
plemental Figure 2).
Acute vaso-occlusive events play a key role in the pathogenesis
of sickle cell–related organ damage and may contribute to SBD.12 In
this study, we demonstrated that H/R stress, mimicking acute VOCs,
increases bone turnover, further promotes osteoclast activity (RankL)
and osteoclastogenesis (Rank), and further suppresses osteogenic
lineage (Runx2, Sparc) (Figure 2 and supplemental Figure 3). In SCD
mice, Zol markedly prevented the H/R-induced increased bone turn-
over (Figure 2), osteoclast activity (RankL), and osteoclast recruit-
ment (Rank) in favor of osteoblastogenesis (Runx2, Sparc) (Figure 3).
This was associated with a downregulation of H/R-induced increased
gene expression of IL-6 and Prx2, in agreement with the reduction in
osteoclast activity (Figure 3B-C). Similar effects of H/R stress and Zol
treatment were also observed in healthy mice, but to a lower extent
comparedwith SCDmice. Our data strongly indicate the key role of
H/R stress in the development of SBD. This is also supported by the
beneﬁcial effects of Zol, which switches off osteoclast activity and
osteoclastogenesis in favor of osteoblastogenesis, limiting bone
impairment related to H/R stress. It is of interest to note that the
positive effects of Zol on bone homeostasis seem to be more
Figure 5. Recurrent acute vaso-occlusive crisis (VOCs) increases bone turnover, downregulates osteoblastogenesis, and upregulates osteoclastogenesis in
sickle cell mice. Zoledronic acid (Zol) prevents bone impairment induced by repeated VOCs. (A) Left panel: representative images of calcein-labeled bone surface. Right
panel: bone formation rate (BFR/BS) and activation frequency (AcF) in healthy (AA) and sickle cell (SS) mice exposed to recurrent (Rec) acute VOCs without and with Zol.
Data are shown as mean6 SD (n5 6); *P, .05 compared with healthy mice; °P, .05 compared with vehicle-treated mice. (B) Runx2, RankL, Rank, and Cathepsin kmRNA
fold changes in AA and SS mice exposed to recurrent (Rec) acute VOCs without and with Zol. Two different housekeeping genes (Gapdh and b-Actin) were used to perform
real-time PCR analysis. Data are shown as mean 6 SD (n 5 6); *P , .05; **P , .005.
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pronounced in SCD mice treated before the exposure to H/R stress
than after an H/R event.
Because SCD patients experience recurrent VOCs, we exposed
SCD mice to repeated H/R stresses. We found that recurrent VOCs
severely affected bone structure and increased bone turnover in SCD
mice compared with either the SCD normoxic group or with SCD
mice exposed to a single VOC (Figures 2, 4, and 5). This was asso-
ciated with upregulation of RankL, Rank, Cathepsin k, and IL-6 as
proresorptive cytokine, and downregulation of Runx2, indicating
increased osteoclast recruitment and activity combined with sup-
pression of osteoblastogenesis (Figure 5). A single dose of Zol,
one month before the repeated VOCs, prevented bone impairment
and bone loss, promoting osteogenic lineage in SCD mice compared
with the vehicle-treated SCD group (Figures 4 and 5).
Based on this evidence, we believe that osteoblasts are the
“sleeping beauty” in the pathogenesis of SBD (Figure 6). Thus, the
therapeutic inhibition of osteoclast activity/osteoclastogenesismight
only be partially effective in the long-term management of SBD in
the absence of stimulating osteogenic lineage treatment, which might
be used as a sequential therapeutic strategy after inhibitors of oste-
oclast activity. Data from SCD mice treated with zoledronic acid,
which is a potent inhibitor of osteoclast activity with a previously
reported action also on osteoblast recruitment,48 support this working
model (Figure 6).
In conclusion, our ﬁndings support the view that SBD is related
to osteoblast impairment, resulting from reduced osteoprogenitors
and osteoblast activity, combined with increased osteoclast activity
(Figure 6). Recurrent VOCs, associated with local oxidative stress
and release of proresorptive cytokines, such as IL-6, further increase
osteoclast activity and osteoclast recruitment associatedwith depres-
sion of osteoblastogenesis, generating a severe bone loss and bone
impairment comparedwith either SCDnormoxic or singleH/R stress
SCD mice (Figure 6). Zol might act on both the osteoclast and os-
teoblast compartments as multimodal therapy to prevent SBD.
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